PTCT analyst estimates

PTC Therapeutics (PTCT) analyst ratings, the average price target and its range, and every firm's latest call.

PTCT analyst ratings and price targets

DateFirmCallTarget
Oct 20, 2026Raymond JamesPTC Therapeutics price target lowered to $106 from $108 at Raymond James$106.00
Oct 15, 2026UBSPTC Therapeutics assumed with a Buy at UBS$90.00
Oct 8, 2026RBC CapitalPTC Therapeutics price target lowered to $75 from $85 at RBC Capital$75.00
Sep 22, 2026Cantor FitzgeraldPTC Therapeutics (PTCT) PT Raised to $137 at Cantor Fitzgerald on ST-920 Acquisition$137.00
Sep 14, 2026Leerink PartnersPTC Therapeutics upgraded to Outperform from Market Perform at Leerink$98.00
Aug 14, 2026BarclaysPTC Therapeutics price target raised to $122 from $120 at Barclays$122.00
Aug 13, 2026Wells FargoPTC Therapeutics price target raised to $109 from $106 at Wells Fargo$109.00
Jul 31, 2026Wells FargoPTC Therapeutics price target raised to $106 from $93 at Wells Fargo$106.00
Jul 31, 2026Morgan StanleyPTC Therapeutics price target raised to $104 from $93 at Morgan Stanley$104.00
Jul 16, 2026Cantor FitzgeraldPTC Therapeutics (PTCT) PT Raised to $130 at Cantor Fitzgerald on PKU LaunchMember Login$130.00
Jul 7, 2026RBC CapitalPTC Therapeutics price target raised to $85 from $82 at RBC Capital$85.00
May 27, 2026JefferiesPTC Therapeutics upgraded to Buy from Hold at Jefferies$85.00
May 8, 2026Morgan StanleyPTC Therapeutics price target raised to $94 from $92 at Morgan Stanley$94.00
Apr 10, 2026Raymond JamesPTC Therapeutics initiated with an Outperform at Raymond James$108.00
Feb 23, 2026Morgan StanleyPTC Therapeutics price target raised to $92 from $90 at Morgan Stanley$92.00

Updated 2026-11-02 23:58 UTC